Letter From the President of LUGPA
LUGPA News
Corrected reference
GENERAL UROLOGY
2025 American Urological Association Microhematuria Guidelines: What Urologists Need to KnowEmily Bochner and Yair Lotan
PROSTATE CANCER
Correlations Between Rapid and Deep Prostate-Specific Antigen Response and Survival After
Benjamin L. Maughan, Yanfang Liu, Suneel Mundle, Xiayi Wang, Lawrence I. Karsh, MD
Anemia Management During PARP Inhibitor Therapy for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Joelle Hamilton, Jason M. Hafron, Benjamin Lowentritt
Comparison of Prostate-Specific Antigen Response Among Patients With de Novo Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone AcetateGordon Brown, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Benjamin H. Lowentritt
Comparison of Deep Prostate-Specific Antigen Response in Patients With de Novo Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs EnzalutamideBenjamin H. Lowentritt, Ibrahim Khilfeh, Dominic Pilon, Shawn Du, Carmine Rossi, Frederic Kinkead, Lilian Diaz, Gordon Brown
MEN’S HEALTH
Urinary and Cancer-Specific Outcomes From Photovaporization of the Prostate in the Setting of Prostate Cancer: A Systematic ReviewShelby N. Harper, Golnaz Venkatraman, Bradley C. Gill
BLADDER CANCER
Home Instillation of UGN-102 for Primary Chemoablation of Recurrent, Low-Grade, Intermediate-Risk Non–Muscle-Invasive Bladder Cancer: A Single-Arm, Open-Label, Phase 3b TrialDavid Morris, Eugene V. Kramolowsky, M. Vincent Bivins, Michael J. Louie, Sunil Raju, Brent Burger, Andrew Meads, Mark Schoenberg
Nivolumab-Induced Guillain-Barré Syndrome in the Treatment of Urothelial CarcinomaDaria Harlamova, Zachariah Taylor, Benjamin E. Jacobs, David B. Cahn
MEET THE EXPERT
Meet the Expert: Tom Jayram, MDLauren Oesterheld
CODING CORNER
Newly FDA-Approved Products: Coding IntegrationMark Painter, Nathan Diller, Kirsten Anderson